MRNS Profile
Marinus Pharmaceuticals, Inc., a pharmaceutical company specializing in rare genetic epilepsies and seizure disorders, is dedicated to developing and commercializing innovative treatments. Founded in 2003 and headquartered in Radnor, Pennsylvania, Marinus focuses on addressing unmet medical needs through its advanced product pipeline and strategic collaborations.
The company's flagship product, ZTALMY, is an oral suspension designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDKL5). This treatment is available for both adult and pediatric patients, providing options for acute and chronic care, as well as in-patient and self-administered settings. ZTALMY targets synaptic and extrasynaptic GABAA receptors, offering potential benefits not only in seizure control but also in addressing associated symptoms such as depression and anxiety.
Marinus Pharmaceuticals is also advancing its lead candidate, ganaxolone, which is under development for a range of genetic epilepsy disorders, including PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome. Ganaxolone's therapeutic potential extends beyond epilepsy, with investigations into its efficacy for depressive disorders also underway. This broad-spectrum approach aims to address multiple facets of neurological and psychiatric conditions.
The company has established key partnerships to enhance its development and commercialization efforts. It holds license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., and has a collaboration agreement with Orion Corporation. These strategic alliances support Marinus in advancing its clinical programs and expanding its reach within the pharmaceutical industry. Through its ongoing research and strategic collaborations, Marinus Pharmaceuticals continues to work towards delivering impactful treatments for patients with challenging neurological disorders.
|
